MX2023000138A - Inhibidores de rip1k. - Google Patents
Inhibidores de rip1k.Info
- Publication number
- MX2023000138A MX2023000138A MX2023000138A MX2023000138A MX2023000138A MX 2023000138 A MX2023000138 A MX 2023000138A MX 2023000138 A MX2023000138 A MX 2023000138A MX 2023000138 A MX2023000138 A MX 2023000138A MX 2023000138 A MX2023000138 A MX 2023000138A
- Authority
- MX
- Mexico
- Prior art keywords
- rip1k
- inhibitors
- compounds
- kinase
- rip1
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 102100022501 Receptor-interacting serine/threonine-protein kinase 1 Human genes 0.000 abstract 3
- 101710138589 Receptor-interacting serine/threonine-protein kinase 1 Proteins 0.000 abstract 3
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
En la presente se divulgan compuestos inhibidores de quinasa, tales como compuestos inhibidores de proteína quinasa 1 que interactúa con el receptor (RIP1), así como también composiciones farmacéuticas y combinaciones que comprenden tales compuestos inhibidores. Los compuestos, composiciones farmacéuticas y/o combinaciones divulgadas pueden usarse para tratar o prevenir una enfermedad o afección asociada a quinasas, particularmente una enfermedad o afección asociada a RIP1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063047194P | 2020-07-01 | 2020-07-01 | |
| PCT/US2021/039112 WO2022005898A1 (en) | 2020-07-01 | 2021-06-25 | Rip1k inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000138A true MX2023000138A (es) | 2023-04-11 |
Family
ID=76972022
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000138A MX2023000138A (es) | 2020-07-01 | 2021-06-25 | Inhibidores de rip1k. |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US11667643B2 (es) |
| EP (1) | EP4175714A1 (es) |
| JP (2) | JP2023532718A (es) |
| KR (1) | KR20230033712A (es) |
| CN (1) | CN116209662B (es) |
| AR (1) | AR122703A1 (es) |
| AU (1) | AU2021300831B2 (es) |
| BR (1) | BR112022026908A2 (es) |
| CA (1) | CA3183296A1 (es) |
| CL (1) | CL2022003812A1 (es) |
| CO (1) | CO2023000051A2 (es) |
| CR (1) | CR20220685A (es) |
| DO (1) | DOP2022000300A (es) |
| EC (1) | ECSP22097749A (es) |
| IL (1) | IL299128A (es) |
| MX (1) | MX2023000138A (es) |
| PE (1) | PE20230730A1 (es) |
| PH (1) | PH12022553615A1 (es) |
| TW (2) | TWI840311B (es) |
| WO (1) | WO2022005898A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022550536A1 (en) | 2019-09-06 | 2023-07-31 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same. |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| WO2023240379A1 (zh) * | 2022-06-13 | 2023-12-21 | 南京医工医药技术有限公司 | 咪唑啉酮衍生物及其用途 |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009023272A1 (en) | 2007-08-15 | 2009-02-19 | President And Fellows Of Harvard College | Heterocyclic inhibitors of necroptosis |
| AR079170A1 (es) * | 2009-12-10 | 2011-12-28 | Lilly Co Eli | Compuesto de ciclopropil-benzamida-imidazo-benzazepina inhibidor de diacil-glicerol aciltransferasa, sal del mismo, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de obesidad o para mejorar la sensibilidad a insulina y compuesto intermedio par |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| EP2968276A4 (en) | 2013-03-15 | 2017-02-15 | President and Fellows of Harvard College | Hybrid necroptosis inhibitors |
| WO2016027253A1 (en) | 2014-08-21 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as rip1 kinase inhibitors as medicaments |
| JP2018505199A (ja) | 2015-02-13 | 2018-02-22 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | （Ｓ）−５−ベンジル−Ｎ−（５−メチル−４−オキソ−２，３，４，５テトラヒドロベンゾ［ｂ］［１，４］オキサゼピン−３−イル）−４Ｈ−１，２，４−トリアゾール−３−カルボキサミドの結晶形 |
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| DK3362449T3 (da) | 2015-10-13 | 2021-07-19 | Inst Nat Sante Rech Med | Sibirilin-derivater til anvendelse til at forebygge og/eller behandle lidelser associeret med cellulær nekroptose |
| AU2016340527B2 (en) | 2015-10-23 | 2020-09-17 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| WO2017109724A1 (en) | 2015-12-21 | 2017-06-29 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| JP6974331B2 (ja) | 2016-02-05 | 2021-12-01 | デナリ セラピューティクス インコーポレイテッドDenali Therapeutics Inc. | 化合物、組成物及び方法 |
| WO2018073193A1 (en) | 2016-10-17 | 2018-04-26 | F. Hoffmann-La Roche Ag | Bicyclic pyridone lactams and methods of use thereof |
| US11072607B2 (en) | 2016-12-16 | 2021-07-27 | Genentech, Inc. | Inhibitors of RIP1 kinase and methods of use thereof |
| CA3052767A1 (en) | 2017-02-27 | 2018-08-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| WO2019134680A1 (zh) | 2018-01-05 | 2019-07-11 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
| KR102808215B1 (ko) | 2018-05-03 | 2025-05-19 | 리겔 파마슈티칼스, 인크. | Rip1 억제 화합물 및 이를 제조하고 사용하는 방법 |
| BR112020022423A2 (pt) | 2018-05-03 | 2021-02-02 | Rigel Pharmaceuticals, Inc. | composto, composição farmacêutica, método, método para tratar uma doença em um indivíduo e método para fabricar o composto |
| CA3104757A1 (en) | 2018-06-26 | 2020-01-02 | Shanghai Institute Of Organic Chemistry, Chinese Academy Of Sciences | Cell necrosis inhibitor, preparation method therefor and use thereof |
| CN111138448B (zh) | 2018-11-02 | 2022-08-02 | 中国科学院上海药物研究所 | 抑制rip1激酶的杂环酰胺及其用途 |
| JP7045526B2 (ja) | 2018-11-02 | 2022-03-31 | 中国科学院上海薬物研究所 | Ｒｉｐ１キナーゼを阻害する複素環状アミド及びその使用 |
| PH12022550536A1 (en) | 2019-09-06 | 2023-07-31 | Rigel Pharmaceuticals Inc | Rip1 inhibitory compounds and methods for making and using the same. |
| JOP20220056A1 (ar) | 2019-09-06 | 2023-01-30 | Rigel Pharmaceuticals Inc | مركبات rip1 تثبيطية وطرق عملها واستخدامها |
| LT4055021T (lt) | 2019-11-07 | 2026-01-12 | Rigel Pharmaceuticals, Inc. | Heterocikliniai junginiai, slopinantys rip1 |
| BR112022010082A2 (pt) * | 2019-11-26 | 2022-08-30 | Univ Texas | Composto de fórmula estrutural i ou sal do mesmo, composição farmacêutica, uso do composto e uso da composição farmacêutica |
| AR121717A1 (es) | 2020-04-02 | 2022-06-29 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
| AR122703A1 (es) | 2020-07-01 | 2022-09-28 | Rigel Pharmaceuticals Inc | Inhibidores de rip1k |
-
2021
- 2021-06-22 AR ARP210101712A patent/AR122703A1/es not_active Application Discontinuation
- 2021-06-22 TW TW112142937A patent/TWI840311B/zh not_active IP Right Cessation
- 2021-06-22 TW TW110122698A patent/TWI824259B/zh active
- 2021-06-25 BR BR112022026908A patent/BR112022026908A2/pt unknown
- 2021-06-25 US US17/358,698 patent/US11667643B2/en active Active
- 2021-06-25 CN CN202180053850.6A patent/CN116209662B/zh active Active
- 2021-06-25 EP EP21743351.5A patent/EP4175714A1/en active Pending
- 2021-06-25 PH PH1/2022/553615A patent/PH12022553615A1/en unknown
- 2021-06-25 MX MX2023000138A patent/MX2023000138A/es unknown
- 2021-06-25 AU AU2021300831A patent/AU2021300831B2/en active Active
- 2021-06-25 KR KR1020237003542A patent/KR20230033712A/ko not_active Ceased
- 2021-06-25 CA CA3183296A patent/CA3183296A1/en active Pending
- 2021-06-25 CR CR20220685A patent/CR20220685A/es unknown
- 2021-06-25 JP JP2022581403A patent/JP2023532718A/ja active Pending
- 2021-06-25 PE PE2022003090A patent/PE20230730A1/es unknown
- 2021-06-25 IL IL299128A patent/IL299128A/en unknown
- 2021-06-25 WO PCT/US2021/039112 patent/WO2022005898A1/en not_active Ceased
-
2022
- 2022-12-29 DO DO2022000300A patent/DOP2022000300A/es unknown
- 2022-12-29 CL CL2022003812A patent/CL2022003812A1/es unknown
- 2022-12-30 EC ECSENADI202297749A patent/ECSP22097749A/es unknown
-
2023
- 2023-01-04 CO CONC2023/0000051A patent/CO2023000051A2/es unknown
- 2023-04-26 US US18/307,181 patent/US12297202B2/en active Active
-
2024
- 2024-10-28 JP JP2024188752A patent/JP2025013995A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230265100A1 (en) | 2023-08-24 |
| BR112022026908A2 (pt) | 2023-03-14 |
| TW202214225A (zh) | 2022-04-16 |
| CN116209662B (zh) | 2026-01-27 |
| PE20230730A1 (es) | 2023-05-03 |
| TW202408480A (zh) | 2024-03-01 |
| ECSP22097749A (es) | 2023-03-31 |
| KR20230033712A (ko) | 2023-03-08 |
| TWI824259B (zh) | 2023-12-01 |
| JP2023532718A (ja) | 2023-07-31 |
| US20220009936A1 (en) | 2022-01-13 |
| DOP2022000300A (es) | 2023-03-31 |
| AU2021300831A1 (en) | 2023-01-19 |
| JP2025013995A (ja) | 2025-01-28 |
| CL2022003812A1 (es) | 2023-08-18 |
| AU2021300831B2 (en) | 2024-11-07 |
| US11667643B2 (en) | 2023-06-06 |
| EP4175714A1 (en) | 2023-05-10 |
| CR20220685A (es) | 2023-03-28 |
| CO2023000051A2 (es) | 2023-04-17 |
| WO2022005898A1 (en) | 2022-01-06 |
| AR122703A1 (es) | 2022-09-28 |
| IL299128A (en) | 2023-02-01 |
| PH12022553615A1 (en) | 2024-03-04 |
| CN116209662A (zh) | 2023-06-02 |
| US12297202B2 (en) | 2025-05-13 |
| TWI840311B (zh) | 2024-04-21 |
| CA3183296A1 (en) | 2022-01-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220246A1 (ar) | مثبطات rip1k | |
| MX2022002719A (es) | Inhibidores heterociclicos de la quinasa rip1. | |
| PH12020551847A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| PH12022550537A1 (en) | Rip1 inhibitory compounds and methods for making and using the same. | |
| PH12020551848A1 (en) | Rip1 inhibitory compounds and methods for making and using the same | |
| PH12022553615A1 (en) | Rip1k inhibitors. | |
| MX2022005509A (es) | Compuestos inhibidores de rip1 heterociclicos. | |
| MX2023010624A (es) | Inhibidores heterociclicos de la cinasa rip1. | |
| AR120412A1 (es) | Compuestos heterocíclicos inhibidores de rip1 |